23andMe

What is 23andMe?

23andMe is a prominent human genome research company that provides a platform for users to explore their ancestry, genealogy, and inherited traits.

Founded by Linda Avey and Anne Wojcicki, the company received significant backing from Google significant backing from Google and its co-founder Sergey Brin, who also happens to be Anne Wojcicki's husband, in the form of a $3.9 million investment as part of a Series A round in May of 2007.

Their investment thesis revolves around making the human genome searchable, aiming to empower individuals with the understanding of their genetic blueprints and providing researchers with organized, searchable genetic data.

Their services have expanded into the healthcare domain, offering insights into genetic health risks and personalized reports that contribute to a more complete understanding of users' health. They operate in a rapidly growing biotech and healthcare sector, where they provide value by offering a platform that facilitates the indexing of genetic information, potentially aiding Google's venture into these multi-billion-dollar markets.

Named after the 23 pairs of chromosomes in humans, 23andMe has evolved to cater to healthcare professionals and consumers interested in personal genetic testing. The company has innovated with offerings that include exome sequencing, biannual blood testing, and genetics-informed clinical care, as well as detailed ancestral analysis with over 3,500 regional breakdowns. Their commitment to genetic research and consumer privacy has sold over 12 million kits, contributing to scientific discoveries and fueling studies that have real-world health impacts.

Additionally, they emphasize user control over their genetic data, underlining their dedication to privacy and the potential for users to make informed health decisions.